| Vol. 12.25 – 28 June, 2023 |
| |
|
|
| Investigators demonstrated a previously unrecognized form of pathogenesis characterized by monocytic disease progression arose from a fundamentally different type of leukemia stem cell (LSC) that was developmentally and clinically distinct from the more well-described primitive LSC. [Cancer Discovery] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists explored the influence of extracellular matrix-derived biomechanical force on breast cancer cell status. Experiments were conducted using 3D collagen, fibrinogen, and Matrigel matrices to investigate the role of mechanical force in tumor development. [Signal Transduction And Targeted Therapy] |
|
|
|
| The authors reported the use of near-infrared-activated small-molecule Pt(IV) photooxidants to directly oxidize intracellular biomolecules in an oxygen-independent manner, achieving controllable and effective elimination of CSCs. [Nature Chemistry] |
|
|
|
| Final results of the Phase I study of acalabrutinib plus STAT3 inhibitor in patients with R/R DLBCL awere reported. Danvatirsen 200 mg intravenous infusion was administered in combination with oral acalabrutinib 100 mg twice daily until progressive disease or unacceptable toxicity. [Clinical Cancer Research] |
|
|
|
| The authors identified CHIP, a chaperone-associated ubiquitin E3 ligase, as a novel negative regulator of SOX2 protein stability and tumorigenic activity in esophageal squamous carcinoma cells. [Oncogene] |
|
|
|
| Researchers investigated the impact of solasonine (SS) on the growth of osteosarcoma (OS) cells. OS cells were treated with different concentrations of SS for 24 hours, and the results showed that SS attenuated the survival of OS cells in a dose-dependent manner. [American Journal Of Chinese Medicine] |
|
|
|
| In silico analysis revealed a higher ZEB1 expression in breast cancer patients that led to decreased overall and relapse-free survival. Scientists generated sorted breast CSC with stable ZEB1 overexpression and/or silencing as well as breast cancer cells with stable ZEB1 overexpression and/or silencing [Biochimica Et Biophysica Acta-Molecular Cell Research] |
|
|
|
| Researchers investigated whether the amino acid 5-aminolevulinic acid could sensitize glioma stem cells to boron neutron capture therapy by enhancing the uptake of boronophenylalanine. [Scientific Reports] |
|
|
|
| The authors analyzed clinical outcomes with elacestrant, compared with endocrine therapy, among women who had previously been treated with a fulvestrant-containing regimen from the recent Phase III EMERALD Study. [Breast Cancer Research And Treatment] |
| |
|
|
|
| GDF11 is a crucial factor in embryogenesis, cell cycle control and apoptosis, inasmuch it mainly targets cell retain stemness features, managing to the cell differentiation and the maturation. [Biochimica Et Biophysica Acta-Reviews On Cancer] |
|
|
|
| Investigators review recent progress on the influence of mitochondria on CSC potential from four aspects: metabolism, dynamics, mitochondrial homeostasis, and reactive oxygen species. [Cell Communication And Signaling] |
|
|
|
|
| The UK’s National Cancer Research Institute (NCRI) has begun winding down operations and working on identifying and securing assets. The NCRI reported that it was becoming increasingly “unsustainable” to continue to fund the charitable organisation. [Clinical Trial Arena] |
|
|
|
| This new granting program, developed by the V Foundation for Cancer Research, sees $8 million in funding invested in cancer research being led by women scientists. Dr. Vu is an associate assistant professor in the faculty of medicine and an assistant professor in the faculty of pharmaceutical sciences at UBC. [The University of British Columbia] |
|
|
|
|
| October 2 – 4, 2023 Boston, Massachusetts, United States |
|
|
|
|
|
| University of Alabama at Birmingham – Birmingham, Alabama, United States |
|
|
|
| Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| University of Texas Health Science Center San Antonio – San Antonio, Texas, United States |
|
|
|
| Pfizer, Inc. – Southern California, United States |
|
|
|
|